Management of microsatellite instability high (MSI-H) gastroesophageal adenocarcinoma
KI Zhou, BA Hanks, JH Strickler - Journal of Gastrointestinal Cancer, 2024 - Springer
Background Gastroesophageal cancer is a major cause of cancer-related mortality
worldwide. Treatment of both early stage and advanced disease remains highly reliant on …
worldwide. Treatment of both early stage and advanced disease remains highly reliant on …
Management of non-colorectal digestive cancers with microsatellite instability
M Zhu, Z Jin, JM Hubbard - Cancers, 2021 - mdpi.com
Simple Summary Microsatellite instability (MSI) is an established predictive biomarker for
immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its …
immune checkpoint inhibitors with potential prognostic value in different types of tumors. Its …
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer
CR Oh, EJ Kim, H Chae, YS Park, MH Ryu, HD Kim… - Gastric Cancer, 2024 - Springer
Background We examined the impact of mismatch repair (MMR) status on efficacy of first-
line fluoropyrimidine plus platinum (FP) chemotherapy in patients with HER2-negative …
line fluoropyrimidine plus platinum (FP) chemotherapy in patients with HER2-negative …
Creation of a quality payment program measure for mismatch repair or microsatellite instability biomarker testing status in colorectal, endometrial, gastroesophageal …
GT Bocsi, J Laudadio, R Jain… - … of Pathology & …, 2024 - meridian.allenpress.com
Context.—Quality measures that are supported by evidence-based clinical practice
guidelines are preferred for assessing the quality of pathologists' practices. Careful testing of …
guidelines are preferred for assessing the quality of pathologists' practices. Careful testing of …
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair
Background We aimed to investigate clinicopathologic factors leading to different clinical
outcomes in patients with deficient mismatch repair protein (d-MMR) gastric cancer (GC) …
outcomes in patients with deficient mismatch repair protein (d-MMR) gastric cancer (GC) …
[HTML][HTML] Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with …
L Ndou, R Chambuso, U Algar, A Boutall, P Goldberg… - Biomedicines, 2024 - mdpi.com
Background: Although genetic testing has improved our ability to diagnose Lynch syndrome
(LS), there is still limited information on the extent of variations in the clinical and genetic …
(LS), there is still limited information on the extent of variations in the clinical and genetic …
Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment
S Kawatoko, K Kohashi, T Torisu, T Sasaki… - … -Research and Practice, 2022 - Elsevier
Solid-type poorly differentiated adenocarcinoma (solid-type-PDA) of the stomach is a unique
histological subtype of “tubular adenocarcinoma”, but little is known about its …
histological subtype of “tubular adenocarcinoma”, but little is known about its …
Prevalence and spectrum of germline pathogenic variants in cancer susceptibility genes among mexican patients with exocrine pancreatic cancer
JL Rodríguez-Olivares, TN Kimball, JM Jeter… - Pancreatology, 2024 - Elsevier
Background Although universal germline genetic testing is recommended for patients with
exocrine pancreatic cancer (PC), access to genetic testing remains limited in low-and middle …
exocrine pancreatic cancer (PC), access to genetic testing remains limited in low-and middle …
[HTML][HTML] A narrative review of the evolving landscape of the management of metastatic gastric cancer: the role of targeted therapies
GM Delgado-Ramos, J Fitzsimons… - Journal of …, 2023 - ncbi.nlm.nih.gov
Methods We performed an extensive review of articles in the PubMed database pertaining to
targeted therapies and immunotherapies in the treatment of metastatic gastric cancer …
targeted therapies and immunotherapies in the treatment of metastatic gastric cancer …
Lynch syndrome screening in patients with young-onset extra-colorectal Lynch syndrome-associated cancers
A Yamada, Y Doi, S Minamiguchi, T Kondo… - International Journal of …, 2024 - Springer
Background Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic
germline variants in mismatch repair (MMR) genes, which predisposes to various types of …
germline variants in mismatch repair (MMR) genes, which predisposes to various types of …